Answers are grounded in this paper and cite their sources.
Regulatory T-cells (Tregs) are increased in chronic lymphocytic leukemia (CLL) and correlates with clinical and biological features of active/progressive disease. However, little is known about their ability to predict the time to first treatment (TFT). We evaluated 75 patients with Rai stage 0 CLL, in whom the absolute number of Tregs was determined at diagnosis, and correlated to main clinical and biological features, as well as to the need of receiving any specific therapy during the course of the disease. After a median follow-up of 30 months, 12 patients (16%) required therapy at some time from the diagnosis. Treated patients showed a significant higher number of peripheral white blood cells and B-lymphocytes, platelet count, cases with unmutated immunoglobulin heavy chain status, and high-risk cytogenetic abnormalities, as well as lower hemoglobin values, than patients who did not need therapy. A greater number of circulating Tregs was detected in treated patients (P < 0.001). Multivariate analysis confirmed that the absolute number of Tregs was an independent predictor of TFT in these patients, the best predictive cut-off being 41/μL. These data show that the absolute Tregs cell number is able to identify Rai stage 0 CLL patients at higher risk of requiring therapy. The clinical course of chronic lymphocytic leukemia (CLL) is highly variable [1]. Some patients live for 20 years or longer, often without need of any treatment, whereas others die from it in a few months. For that reason, many efforts have been made to search prognostic factors able to recognize at diagnosis patients with more (or less) aggressive disease [2]. Among them, clinical staging has been for long time a good guideline as to the treatment plans and outcome of CLL [3-5]. In 1975, Rai et al. drew a classification system for CLL patients in which five distinct stages were mainly based on the progressive clinical involvement of lymph nodes, spleen, liver, and anemia and/or thrombocytopenia, as expression of bone marrow infiltration [3]. According to this system, lymphocytosis alone identifies the lowest risk patients within the stage 0, because of a longer median survival (more than 10 years) with respect to intermediate (median 7 years) and high risk (1–2 years) CLL. Rai staging system withstands the test of time despite the advent of several new “biologic” prognostic indicators, such as immunoglobulin heavy chain (IgVH) mutational status, ζ-chain associated protein of 70 kD (ZAP-70) and CD38 expressions, and cytogenetic or molecular abnormalities [2, 6]. Regulatory T-cells (Tregs) are a small subset of T-lymphocytes with immune suppression activity [7]. They function as cells suppressing antitumor immunity, and their number in peripheral blood has been shown to be increased in solid tumors and hematologic malignancies as well [8]. We and others have shown that Tregs are increased in CLL and correlate with several clinical–biological features of active/progressive disease [9-11]. However, little is known on the ability of Tregs to predict the time to first treatment (TFT) in patients with early stage/low risk CLL. To investigate this specific topic, from August 2008 to August 2011, we evaluated a cohort of 75 consecutive patients with Rai stage 0 CLL, in whom the absolute number of Tregs was determined at the time of diagnosis and correlated to main clinical and biological features, as well as to the need of receiving any specific therapy during the course of the disease. Clinical and biological characteristics of the entire cohort and those of the same patients grouped according to therapy or no therapy requirement, during the period of observation, are reported in Table I. Overall, 12 patients (16%) did reach a point during the follow-up (median time: 16 months; range 2–34 months) to need therapy, according to the International Workshop on CLL (IWCLL) criteria [5]. One patient was treated after just 2 months from diagnosis because of a sudden and relevant increase of lymphocyte count (from 105,400 to 189,200/μL). Three patients doubled lymphocytes after 5, 6, and 7 months, respectively, and then treated. The remaining eight patients underwent therapy because of they shifted to a more advanced Rai clinical stage (lymph-node enlargement and, in two cases, spleen enlargement), along with a relevant, progressive lymphocyte increase and appearance of clinical symptoms, mainly weight loss and fever. None of these events occurred in the cohort of patients who did not receive therapy. Age, gender, and lactate dehydrogenase (LDH) serum levels were not statistically different between untreated and treated patient groups (P < 0.14 and 0.36, respectively). Treated patients, however, showed a higher number of total peripheral white blood cells and B-cell lymphocytes (P < 0.001), lower hemoglobin values (P < 0.015) and higher platelet count (P < 0.012). With respect to other biological prognostic factors, a greater number of cases with unmutated IgVH status (P < 0.025) and carrying high risk cytogenetic abnormalities (P < 0.05) was found in patients requiring therapy. By contrast, ZAP-70 and CD38 expression was not able to show any statistically significant difference between the two groups (Table I). Median follow-up was 30 months (range 2–36 months). Of interest, a greater number of circulating Tregs was detected at diagnosis in patients who subsequently required a treatment (P < 0.001). As shown in Table II, multivariate analysis confirmed that the absolute number of Tregs was an independent predictor of TFT in our Rai Stage 0 CLL patients (P < 0.001). Finally, the best predictive cutoff of Tregs cells was 41/μL, as determined by receiver-operating characteristic (ROC) analysis (Fig. 1). ROC curve graphically showing the trade-offs between sensitivity and specificity for different cutoffs used to discriminate between positive and negative cases (i.e., treatment demand vs. no treatment demand patients). The best predictive cutoff of circulating Treg cell number seems to be in the range from ≥40 to ≥42/μL. The result of cutoff ≥41/μL clearly shows the best predictive power among the others. Cutoff ≥41/μL has a sensitivity of 92% and a specificity of 90%. Cutoff ≥40/μL has same sensitivity but less specificity (86%), otherwise cutoff ≥42/μL has less sensitivity (83%) but the same specificity. The AUC of ROC curve is 0.96 (standard error 0.0219; 95% CI 0.92–1) showing a good predictive value. Tregs are a small subset of T-lymphocytes acting as cells suppressing antitumor immunity [7]. Their number in peripheral blood has been shown to be increased in solid tumors and hematologic malignancies as well [8]. Moreover, Tregs have been found increased in CLL and correlated with several clinical–biological features of active/progressive disease [9-11]. However, little is known on a possible relationship between Tregs and TFT in patients with early stage/low risk CLL. Tregs were originally defined based on the combined expression of CD4 and interleukin (IL)-2 receptor (CD25) at high density [11]. Subsequently, the nuclear factor Foxp3 has been recognized as a master regulation and lineage-specification factor for Tregs [12]. However, its routine use is limited by the intracellular localization and consequent difficulties in standardizing protocols and results. More recently, low expression of the IL-7 receptor (CD127) has been recognized as a further Tregs marker [13, 14]. Taken these observations into account, we utilized the combination of CD4/CD25/CD127 MoAbs to evaluate by means of flow cytometry the number of circulating Tregs in our patients. Using such an approach, we found that circulating Tregs were higher in the group of low risk, Rai stage 0 CLL patients who, at some time of their disease course, progressed and required therapy. This is in line with previous observations evidencing that not only Tregs are increased in CLL but also that their number correlates with other clinical and biological features of greater aggressiveness, such as higher B-cell lymphocytosis, unfavorable cytogenetic abnormalities and IgVH unmutated status. Furthermore, in our hands, multivariate analysis confirmed the strong independent prognostic significance of the absolute number of Tregs in identifying those patients with stage 0 CLL with a higher risk to require a treatment in a relatively short time. In particular, ROC analysis identified a cell number of 41/μL as the best predictive cutoff level of circulating Tregs, with high sensitivity (92%) and high specificity (90%) as well. Weiss et al. have recently suggested that Tregs may predict TFT in low-intermediate risk CLL [15]. However, some main issues make our data different from that reported by these authors. First of all, we focused exclusively on Rai stage 0 CLL (a homogeneous setting of patients in which prognostication at diagnosis may be particularly relevant in the clinical practice), while that study also included stage I-II patients. Furthermore, we examined Tregs exclusively at diagnosis and not at some time of the disease. Though it was suggested that no significant changes in Tregs evaluation occur in single patients during the course of CLL [15], we believe that an initial assessment of Tregs may provide more homogeneous findings. Finally, we preferred to use the absolute number of Tregs, instead of their percentage, as we have previously found that only the absolute number of these cells may be predictive of progressive disease [11]. The pathogenic role of Tregs in CLL is still under investigation. Despite the fact that CLL is a cancer of the B-cell compartment of the immune system, a T-cell dysregulation in this disorder is well known [16, 17]. It is generally thought that T-cell immune-surveillance of leukemic cells is derailed and that the increased number of Tregs observed in neoplastic patients (both in solid and blood cancers) is directly correlated to the tumor burden [16, 18]. On the other hand, the increased Treg cell numbers could result indirectly from intrinsically more aggressive CLL and thus be a consequence and not the cause of aggressive disease or its progression. In conclusion, our data, despite obtained on a relatively small population of CLL patients with a short follow-up and a low number of treatment events, suggest that an increased absolute number of Tregs found at diagnosis may represent an independent prognostic factor for predicting a shorter TFT of Rai stage 0 CLL patients. In light of this, another issue to clarify will be to verify whether the same phenomenon occurs in the setting of monoclonal B-cell lymphocytosis (MBL), in which a lower absolute number of Tregs, as compared to CLL patients, but slightly higher than normal subjects, has been found [19]. If so, this would provide further support to the hypothesis that more the circulating Tregs number increases, more the tumor disease burden/aggressiveness progresses (evolving from MBL to low to intermediate to high risk CLL). In other words, the increased presence of Tregs might be directly related to the expansion of the neoplastic clone, probably resulting in a more potent inhibition of immune system tumor control. Enumerating Tregs at diagnosis might, therefore, contribute to better stratify the prognosis of patients with early stage CLL and MBL and even to define a new possible therapeutic target [20]. Our observation, however, remains still preliminary and needs to be confirmed by other investigators, on larger cohorts of Rai Stage 0 CLL patients with prolonged follow-up, before it can be recommended for general usage in the clinical practice. Ethylenediaminetetraacetic acid (EDTA)-anticoagulated peripheral blood samples were obtained from 75 consecutive patients with CLL staged as Rai 0 at diagnosis. The main clinical and biological features of patients are summarized in Table I. The study protocol was approved by the Local Ethical Committee and all subjects recruited into the study gave written informed consent. Tregs were numbered by means of flow cytometry as follows: 100 μL of whole blood were incubated at 4°C in the dark for 30 min with 10 μL of each of the following directly conjugated monoclonal antibodies (MoAbs): CD4-PerCP (perydinin chlorophyll protein complex)/CD127-PE (phycoerythrin)/CD25-PE-Cy7 (PE-Cyanine 7)/CD45-Apc-Cy7 (allophycocyanin-Cy7). All MoAbs were purchased from Becton-Dickinson Biosciences (BDB, San Jose, CA). After lysis of red blood cells and repeated washings, the samples were analyzed by flow cytometry, by acquiring a minimum of 20,000 events for each sample, using a FACSCanto II cytometer (BDB). All subsequent analyses were performed using FACS-Diva software (BDB). Treg cells were evaluated according to the gating strategy protocol previously described by Baecher-Allan et al. (CD4+ cells expressing high levels of CD25) modified by the addition of CD127 monoclonal antibody [21]. Overall, Treg cells were defined by the expression of CD4, CD25 at high density and CD127 at low density or undetectable levels [13]. This gating strategy was chosen because it better discriminates between Treg cells and activated T-cells that normally upregulate CD25 antigen [14]. The absolute Treg cell count in each sample was calculated by multiplying their percentage number, evaluated on all (B, T, and NK) lymphocytes, by the absolute lymphocyte number as provided by the hematology analyzer (dual platform approach). Continuous variables are reported as means, standard deviations, medians, and range. Comparisons were performed by use of simple t-test for parametric data with Mann–Whitney U-test for nonparametric data. Categorical variables are reported as count and percentage and were compared by the use of the χ2 or Fisher exact tests. Multivariate Cox proportional hazards model was used to study the independent prognostic factors of “need of treatment” adjusted for age, Treg cell number, white blood cell count, B-cell lymphocytosis, platelets, IgVH mutational status, hemoglobin, and cytogenetic abnormalities, these variables being statistically significant in univariate analyses. Unadjusted and adjusted hazard ratio and their 95% confidence interval (CI) are provided. ROC curves and the areas under the curves (AUC) were calculated to assess the accuracy of the tests. A ROC curve graphically shows the trade-offs between sensitivity and specificity for different cutoffs used to discriminate between positive and negative cases (i.e., treated vs. untreated cases). The AUC can be understood as an estimate of the probability that the biomarker being tested correctly ranks a case underwent therapy higher than a case without therapy demand and, therefore, indexes the discriminating power of the biomarker. Differences between the AUC were tested for statistical significance based on the estimated areas and their standard errors. Statistical significance was defined as P < 0.05. Statistical analyses were performed using STATA package version 11.0 (StataCorp). Giovanni D'Arena giovannidarena@libero.it*, Fiorella D'Auria , Vittorio Simeon , Luca Laurenti§, Silvia Deaglio¶, Giovanna Mansueto*, Maria Ilaria Del Principe**, Teodora Statuto , Giuseppe Pietrantuono*, Roberto Guariglia*, Idanna Innocenti§, Maria Carmen Martorelli*, Oreste Villani*, Vincenzo De Feo , Giovanni Del Poeta**, Pellegrino Musto*, * Department of Onco-Hematology, IRCCS “Centro di Riferimento Oncologico della Basilicata,” Rionero in Vulture, Italy, Laboratory of Clinical Research and Advanced Diagnostics, IRCCS “Centro di Riferimento Oncologico della Basilicata,” Rionero in Vulture, Italy, Laboratory of Preclinical and Translational Research, IRCCS “Centro di Riferimento Oncologico della Basilicata,” Rionero in Vulture, Italy, § Hematology Institute, Catholic University of “Sacred Hearth,” Rome, Italy, ¶ Human Genetics Foundation & University of Turin, Italy, ** Hematology Institute, University of Tor Vergata, Rome, Italy, Department of Pharmacology, University of Salerno, Italy.
No takes yet. Share an insight, caveat, or question.
D’Arena et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: